


1  
2  
3  
4 **GEMZAR<sup>®</sup>**  
5 **(GEMCITABINE HCL)**  
6 **FOR INJECTION**

7  
8 **DESCRIPTION**

9 Gemzar<sup>®</sup> (gemcitabine HCl) is a nucleoside analogue that exhibits antitumor activity. Gemcitabine HCl is 2'-  
10 deoxy-2',2'-difluorocytidine monohydrochloride ( $\beta$ -isomer).

11 The structural formula is as follows:  
12



13  
14  
15 The empirical formula for gemcitabine HCl is C<sub>9</sub>H<sub>11</sub>F<sub>2</sub>N<sub>3</sub>O<sub>4</sub> • HCl. It has a molecular weight of 299.66.

16 Gemcitabine HCl is a white to off-white solid. It is soluble in water, slightly soluble in methanol, and practically  
17 insoluble in ethanol and polar organic solvents.

18 The clinical formulation is supplied in a sterile form for intravenous use only. Vials of Gemzar contain either 200  
19 mg or 1 g of gemcitabine HCl (expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and  
20 sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium  
21 hydroxide may have been added for pH adjustment.  
22

23 **CLINICAL PHARMACOLOGY**

24 Gemcitabine exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and also  
25 blocking the progression of cells through the G1/S-phase boundary. Gemcitabine is metabolized intracellularly by  
26 nucleoside kinases to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effect  
27 of gemcitabine is attributed to a combination of two actions of the diphosphate and the triphosphate nucleosides,  
28 which leads to inhibition of DNA synthesis. First, gemcitabine diphosphate inhibits ribonucleotide reductase, which  
29 is responsible for catalyzing the reactions that generate the deoxynucleoside triphosphates for DNA synthesis.  
30 Inhibition of this enzyme by the diphosphate nucleoside causes a reduction in the concentrations of  
31 deoxynucleotides, including dCTP. Second, gemcitabine triphosphate competes with dCTP for incorporation into  
32 DNA. The reduction in the intracellular concentration of dCTP (by the action of the diphosphate) enhances the  
33 incorporation of gemcitabine triphosphate into DNA (self-potential). After the gemcitabine nucleotide is  
34 incorporated into DNA, only one additional nucleotide is added to the growing DNA strands. After this addition,  
35 there is inhibition of further DNA synthesis. DNA polymerase epsilon is unable to remove the gemcitabine  
36 nucleotide and repair the growing DNA strands (masked chain termination). In CEM T lymphoblastoid cells,  
37 gemcitabine induces internucleosomal DNA fragmentation, one of the characteristics of programmed cell death.

38 Gemcitabine demonstrated dose-dependent synergistic activity with cisplatin *in vitro*. No effect of cisplatin on  
39 gemcitabine triphosphate accumulation or DNA double-strand breaks was observed. *In vivo*, gemcitabine showed  
40 activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity

41 was seen with the NCI-H460 or NCI-H520 xenografts. Gemcitabine was synergistic with cisplatin in the Lewis lung  
42 murine xenograft. Sequential exposure to gemcitabine 4 hours before cisplatin produced the greatest interaction.

43 *Human Pharmacokinetics*—Gemcitabine disposition was studied in five patients who received a single 1000  
44 mg/m<sup>2</sup>/30 minute infusion of radiolabeled drug. Within one (1) week, 92% to 98% of the dose was recovered,  
45 almost entirely in the urine. Gemcitabine (<10%) and the inactive uracil metabolite, 2'-deoxy-2', 2'-difluorouridine  
46 (dFdU), accounted for 99% of the excreted dose. The metabolite dFdU is also found in plasma. Gemcitabine plasma  
47 protein binding is negligible.

48 The pharmacokinetics of gemcitabine were examined in 353 patients, about 2/3 men, with various solid tumors.  
49 Pharmacokinetic parameters were derived using data from patients treated for varying durations of therapy given  
50 weekly with periodic rest weeks and using both short infusions (<70 minutes) and long infusions (70 to 285  
51 minutes). The total Gemzar dose varied from 500 to 3600 mg/m<sup>2</sup>.

52 Gemcitabine pharmacokinetics are linear and are described by a 2-compartment model. Population  
53 pharmacokinetic analyses of combined single and multiple dose studies showed that the volume of distribution of  
54 gemcitabine was significantly influenced by duration of infusion and gender. Clearance was affected by age and  
55 gender. Differences in either clearance or volume of distribution based on patient characteristics or the duration of  
56 infusion result in changes in half-life and plasma concentrations. Table 1 shows plasma clearance and half-life of  
57 gemcitabine following short infusions for typical patients by age and gender.

58  
59

**Table 1**  
**Gemcitabine Clearance and Half-Life for the "Typical" Patient**

Age	Clearance		Half-Life <sup>a</sup>	
	Men (L/hr/m <sup>2</sup> )	Women (L/hr/m <sup>2</sup> )	Men (min)	Women (min)
29	92.2	69.4	42	49
45	75.7	57.0	48	57
65	55.1	41.5	61	73
79	40.7	30.7	79	94

60 <sup>a</sup>Half-life for patients receiving a short infusion (<70 min)

61 Gemcitabine half-life for short infusions ranged from 32 to 94 minutes, and the value for long infusions varied  
62 from 245 to 638 minutes, depending on age and gender, reflecting a greatly increased volume of distribution with  
63 longer infusions. The lower clearance in women and the elderly results in higher concentrations of gemcitabine for  
64 any given dose.

65 The volume of distribution was increased with infusion length. Volume of distribution of gemcitabine was 50  
66 L/m<sup>2</sup> following infusions lasting <70 minutes, indicating that gemcitabine, after short infusions, is not extensively  
67 distributed into tissues. For long infusions, the volume of distribution rose to 370 L/m<sup>2</sup>, reflecting slow equilibration  
68 of gemcitabine within the tissue compartment.

69 The maximum plasma concentrations of dFdU (inactive metabolite) were achieved up to 30 minutes after  
70 discontinuation of the infusions and the metabolite is excreted in urine without undergoing further  
71 biotransformation. The metabolite did not accumulate with weekly dosing, but its elimination is dependent on renal  
72 excretion, and could accumulate with decreased renal function.

73 The effects of significant renal or hepatic insufficiency on the disposition of gemcitabine have not been assessed.  
74 The active metabolite, gemcitabine triphosphate, can be extracted from peripheral blood mononuclear cells. The  
75 half-life of the terminal phase for gemcitabine triphosphate from mononuclear cells ranges from 1.7 to 19.4 hours.

76 *Drug Interactions*—When gemcitabine (1250mg/m<sup>2</sup> on Days 1 and 8) and cisplatin (75mg/m<sup>2</sup> on Day 1) was  
77 administered in NSCLC patients, the clearance of gemcitabine on Day 1 was 128 L/hr/m<sup>2</sup> and on Day 8 was  
78 107 L/hr/m<sup>2</sup>. The clearance of cisplatin in the same study was reported to be 3.94 mL/min/m<sup>2</sup> with a corresponding  
79 half-life of 134 hours (see **PRECAUTIONS—Drug Interactions**).

80  
81

## CLINICAL STUDIES

82 *Non-Small Cell Lung Cancer (NSCLC)*—Data from two randomized clinical studies (657 patients) support the use  
83 of Gemzar in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic  
84 NSCLC.

85 Gemzar plus cisplatin versus cisplatin: This study was conducted in Europe, the U.S., and Canada in 522 patients  
86 with inoperable Stage IIIA, IIIB, or IV NSCLC who had not received prior chemotherapy. Gemzar 1000 mg/m<sup>2</sup> was

87 administered on days 1, 8, and 15 of a twenty-eight day cycle with cisplatin 100 mg/m<sup>2</sup> administered on day 1 of  
88 each cycle. Single-agent cisplatin 100 mg/m<sup>2</sup> was administered on day 1 of each 28-day cycle. The primary end  
89 point was survival. Patient demographics are shown in Table 2. An imbalance with regard to histology was observed  
90 with 48% of patients on the cisplatin arm and 37% of patients on the Gemzar plus cisplatin arm having  
91 adenocarcinoma.

92 The Kaplan-Meier survival curve is shown in Figure 1. Median survival time on the Gemzar plus cisplatin arm  
93 was 9.0 months compared to 7.6 months on the single-agent cisplatin arm (Logrank p=0.008, two-sided). Median  
94 time to disease progression was 5.2 months on the Gemzar plus cisplatin arm compared to 3.7 months on the  
95 cisplatin arm (Logrank p=0.009, two-sided). The objective response rate on the Gemzar plus cisplatin arm was 26%  
96 compared to 10% with cisplatin (Fisher's Exact p<0.0001, two-sided). No difference between treatment arms with  
97 regard to duration of response was observed.


98 Gemzar plus cisplatin versus etoposide plus cisplatin: A second, multicenter, study in Stage IIIB or IV NSCLC  
99 randomized 135 patients to Gemzar 1250 mg/m<sup>2</sup> on days 1 and 8, and cisplatin 100 mg/m<sup>2</sup> on day 1 of a 21-day  
100 cycle or to etoposide 100 mg/m<sup>2</sup> I.V. on days 1, 2, and 3 and cisplatin 100 mg/m<sup>2</sup> on day 1 on a 21-day cycle (Table  
101 2).

102 There was no significant difference in survival between the two treatment arms (Logrank p=0.18, two-sided). The  
103 median survival was 8.7 months for the Gemzar plus cisplatin arm versus 7.0 months for the etoposide plus cisplatin  
104 arm. Median time to disease progression for the Gemzar plus cisplatin arm was 5.0 months compared to 4.1 months  
105 on the etoposide plus cisplatin arm (Logrank p=0.015, two-sided). The objective response rate for the Gemzar plus  
106 cisplatin arm was 33% compared to 14% on the etoposide plus cisplatin arm (Fisher's Exact p=0.01, two-sided).

107 Quality of Life (QOL): QOL was a secondary endpoint in both randomized studies. In the Gemzar plus cisplatin  
108 versus cisplatin study, QOL was measured using the FACT-L, which assessed physical, social, emotional and  
109 functional well-being, and lung cancer symptoms. In the study of Gemzar plus cisplatin versus etoposide plus  
110 cisplatin, QOL was measured using the EORTC QLQ-C30 and LC13, which assessed physical and psychological  
111 functioning and symptoms related to both lung cancer and its treatment. In both studies no significant differences  
112 were observed in QOL between the Gemzar plus cisplatin arm and the comparator arm.

**Figure 1**

**Kaplan-Meier Survival Curve in  
Gemzar plus Cisplatin versus Cisplatin NSCLC Study (N=522)**



115  
116

**Table 2**  
**Randomized Trials of Combination Therapy with Gemzar plus Cisplatin in NSCLC**

Trial	28-day Schedule <sup>a</sup>			21-day Schedule <sup>b</sup>		
	Gemzar/ Cisplatin	Cisplatin		Gemzar/ Cisplatin	Cisplatin/ Etoposide	
Number of patients	260	262		69	66	
Male	182	186		64	61	
Female	78	76		5	5	
Median age, years	62	63		58	60	
Range	36 to 88	35 to 79		33 to 76	35 to 75	
Stage IIIA	7%	7%		N/A	N/A	
Stage IIIB	26%	23%		48%	52%	
Stage IV	67%	70%		52%	49%	
Baseline KPS <sup>c</sup> 70 to 80	41%	44%		45%	52%	
Baseline KPS <sup>c</sup> 90 to 100	57%	55%		55%	49%	
Survival			p=0.008			p=0.18
Median, months	9.0	7.6		8.7	7.0	
(95% C.I.) months	8.2, 11.0	6.6, 8.8		7.8, 10.1	6.0, 9.7	
Time to Disease Progression			p=0.009			p=0.015
Median, months	5.2	3.7		5.0	4.1	
(95% C.I.) months	4.2, 5.7	3.0, 4.3		4.2, 6.4	2.4, 4.5	
Tumor Response	26%	10%	p<0.0001 <sup>d</sup>	33%	14%	p=0.01 <sup>d</sup>

117

118  
119  
120  
121  
122  
123  
124  
125  
126

<sup>a</sup>28-day schedule— Gemzar plus cisplatin: Gemzar 1000 mg/m<sup>2</sup> on Days 1, 8, and 15 and cisplatin 100 mg/m<sup>2</sup> on Day 1 every 28 days; Single-agent cisplatin: cisplatin 100 mg/m<sup>2</sup> on Day 1 every 28 days

<sup>b</sup>21-day schedule— Gemzar plus cisplatin: Gemzar 1250 mg/m<sup>2</sup> on Days 1 and 8 and cisplatin 100 mg/m<sup>2</sup> on Day 1 every 21 days; Etoposide plus Cisplatin: cisplatin 100 mg/m<sup>2</sup> on Day 1 and I.V. etoposide 100 mg/m<sup>2</sup> on Days 1, 2, and 3 every 21 days

<sup>c</sup>Karnofsky Performance Status

<sup>d</sup>p-value for tumor response was calculated using the 2-sided Fisher's exact test for difference in binomial proportions.

All other p-values were calculated using the Logrank test for difference in overall time to an event.

N/A Not applicable

127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148

*Pancreatic Cancer*—Data from two clinical trials evaluated the use of Gemzar in patients with locally advanced or metastatic pancreatic cancer. The first trial compared Gemzar to 5-Fluorouracil (5-FU) in patients who had received no prior chemotherapy. A second trial studied the use of Gemzar in pancreatic cancer patients previously treated with 5-FU or a 5-FU-containing regimen. In both studies, the first cycle of Gemzar was administered intravenously at a dose of 1000 mg/m<sup>2</sup> over 30 minutes once weekly for up to 7 weeks (or until toxicity necessitated holding a dose) followed by a week of rest from treatment with Gemzar. Subsequent cycles consisted of injections once weekly for 3 consecutive weeks out of every 4 weeks.

The primary efficacy parameter in these studies was "clinical benefit response", which is a measure of clinical improvement based on analgesic consumption, pain intensity, performance status and weight change. Definitions for improvement in these variables were formulated prospectively during the design of the two trials. A patient was considered a clinical benefit responder if either:

- i) the patient showed a ≥50% reduction in pain intensity (Memorial Pain Assessment Card) or analgesic consumption, or a twenty point or greater improvement in performance status (Karnofsky Performance Scale) for a period of at least four consecutive weeks, without showing any sustained worsening in any of the other parameters. Sustained worsening was defined as four consecutive weeks with either any increase in pain intensity or analgesic consumption or a 20 point decrease in performance status occurring during the first 12 weeks of therapy.

OR:

- ii) the patient was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥ 7% increase maintained for ≥ 4 weeks) not due to fluid accumulation.

The first study was a multi-center (17 sites in US and Canada), prospective, single-blinded, two-arm, randomized, comparison of Gemzar and 5-FU in patients with locally advanced or metastatic pancreatic cancer who had received

149 no prior treatment with chemotherapy. 5-FU was administered intravenously at a weekly dose of 600 mg/m<sup>2</sup> for 30  
 150 minutes. The results from this randomized trial are shown in Table 3. Patients treated with Gemzar had statistically  
 151 significant increases in clinical benefit response, survival, and time to disease progression compared to 5-FU. The  
 152 Kaplan-Meier curve for survival is shown in Figure 2. No confirmed objective tumor responses were observed with  
 153 either treatment.

154  
 155 **Table 3**  
 156 **Gemzar Versus 5-FU in Pancreatic Cancer**

	Gemzar	5-FU	
Number of patients	63	63	
Male	34	34	
Female	29	29	
Median age	62 years	61 years	
Range	37 to 79	36 to 77	
Stage IV disease	71.4%	76.2%	
Baseline KPS <sup>a</sup> ≤70	69.8%	68.3%	
Clinical benefit response	22.2% (N <sup>c</sup> = 14)	4.8% (N = 3)	p = 0.004
Survival			p = 0.0009
Median	5.7 months	4.2 months	
6-month probability <sup>b</sup>	(N = 30) 46%	(N = 19) 29%	
9-month probability <sup>b</sup>	(N = 14) 24%	(N = 4) 5%	
1-year probability <sup>b</sup>	(N = 9) 18%	(N = 2) 2%	
Range	0.2 to 18.6 months	0.4 to 15.1+ months	
95% C.I. of the median	4.7 to 6.9 months	3.1 to 5.1 months	
Time to Disease Progression			p = 0.0013
Median	2.1 months	0.9 months	
Range	0.1+ to 9.4 months	0.1 to 12.0+ months	
95% C.I. of the median	1.9 to 3.4 months	0.9 to 1.1 months	

157  
 158 <sup>a</sup>Karnofsky Performance Status

159 <sup>b</sup>Kaplan-Meier estimates

160 <sup>c</sup>N = number of patients

161 + No progression at last visit; remains alive.

162 The p-value for clinical benefit response was calculated using the 2-sided test for difference in binomial

163 proportions. All other p-values were calculated using the Logrank test for difference in overall time to an event.

164  
 165 Clinical benefit response was achieved by 14 patients treated with Gemzar and 3 patients treated with 5-FU. One  
 166 patient on the Gemzar arm showed improvement in all three primary parameters (pain intensity, analgesic  
 167 consumption, and performance status). Eleven patients on the Gemzar arm and two patients on the 5-FU arm  
 168 showed improvement in analgesic consumption and/or pain intensity with stable performance status. Two patients  
 169 on the Gemzar arm showed improvement in analgesic consumption or pain intensity with improvement in  
 170 performance status. One patient on the 5-FU arm was stable with regard to pain intensity and analgesic consumption  
 171 with improvement in performance status. No patient on either arm achieved a clinical benefit response based on  
 172 weight gain.


173

174

175

176  
177  
178  
179  
180

**Figure 2**  
**Kaplan-Meier Survival Curve**



181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197

The second trial was a multi-center (17 U.S. and Canadian centers), open-label study of Gemzar in 63 patients with advanced pancreatic cancer previously treated with 5-FU or a 5-FU-containing regimen. The study showed a clinical benefit response rate of 27% and median survival of 3.9 months.

*Other Clinical Studies*—When Gemzar was administered more frequently than once weekly or with infusions longer than 60 minutes, increased toxicity was observed. Results of a Phase 1 study of Gemzar to assess the maximum tolerated dose (MTD) on a daily x 5 schedule showed that patients developed significant hypotension and severe flu-like symptoms that were intolerable at doses above 10 mg/m<sup>2</sup>. The incidence and severity of these events were dose-related. Other Phase 1 studies using a twice-weekly schedule reached MTDs of only 65 mg/m<sup>2</sup> (30-minute infusion) and 150 mg/m<sup>2</sup> (5-minute bolus). The dose-limiting toxicities were thrombocytopenia and flu-like symptoms, particularly asthenia. In a Phase 1 study to assess the maximum tolerated infusion time, clinically significant toxicity, defined as myelosuppression, was seen with weekly doses of 300 mg/m<sup>2</sup> at or above a 270-minute infusion time. The half-life of gemcitabine is influenced by the length of the infusion (see **CLINICAL PHARMACOLOGY**) and the toxicity appears to be increased if Gemzar is administered more frequently than once weekly or with infusions longer than 60 minutes (see **WARNINGS**).

## INDICATIONS AND USAGE

### Therapeutic Indications

**Non-Small Cell Lung Cancer**—Gemzar is indicated in combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer.

**Pancreatic Cancer**—Gemzar is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemzar is indicated for patients previously treated with 5-FU.

### CONTRAINDICATION

Gemzar is contraindicated in those patients with a known hypersensitivity to the drug (see **ADVERSE REACTIONS--Allergic**).

### WARNINGS

**Caution**—Prolongation of the infusion time beyond 60 minutes and more frequent than weekly dosing have been shown to increase toxicity (see **CLINICAL STUDIES**).

**Hematology**—Gemzar can suppress bone marrow function as manifested by leukopenia, thrombocytopenia and anemia (see **ADVERSE REACTIONS**), and myelosuppression is usually the dose-limiting toxicity. Patients should be monitored for myelosuppression during therapy. See **DOSAGE AND ADMINISTRATION** for recommended dose adjustments.

**Pulmonary**—Pulmonary toxicity has been reported with the use of Gemzar. In cases of severe lung toxicity, Gemzar therapy should be discontinued immediately and appropriate supportive care measures instituted (see **Pulmonary** under Single-Agent Use and under Post-marketing experience in **ADVERSE REACTIONS** section).

**Renal**—HUS and or renal failure have been reported following one or more doses of Gemzar. Renal failure leading to death or requiring dialysis, despite discontinuation of therapy, has been rarely reported. The majority of the cases of renal failure leading to death were due to HUS (see **Renal** under Single-Agent Use and under Post-marketing experience in **ADVERSE REACTIONS** section).

**Hepatic**—Serious hepatotoxicity, including liver failure and death has been reported very rarely in patients receiving Gemzar alone or in combination with other potentially hepatotoxic drugs (see **Hepatic** under Single-Agent Use and under Post-marketing experience in **ADVERSE REACTIONS** section).

**Pregnancy**—Pregnancy Category D. Gemzar can cause fetal harm when administered to a pregnant woman. Gemcitabine is embryotoxic causing fetal malformations (cleft palate, incomplete ossification) at doses of 1.5 mg/kg/day in mice (about 1/200 the recommended human dose on a mg/m<sup>2</sup> basis). Gemcitabine is fetotoxic causing fetal malformations (fused pulmonary artery, absence of gall bladder) at doses of 0.1 mg/kg/day in rabbits (about 1/600 the recommended human dose on a mg/m<sup>2</sup> basis). Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays. There are no studies of Gemzar in pregnant women. If Gemzar is used during pregnancy, or if the patient becomes pregnant while taking Gemzar, the patient should be apprised of the potential hazard to the fetus.

### PRECAUTIONS

**General**—Patients receiving therapy with Gemzar should be monitored closely by a physician experienced in the use of cancer chemotherapeutic agents. Most adverse events are reversible and do not need to result in discontinuation, although doses may need to be withheld or reduced. There was a greater tendency in women, especially older women, not to proceed to the next cycle.

**Laboratory Tests**—Patients receiving Gemzar should be monitored prior to each dose with a complete blood count (CBC), including differential and platelet count. Suspension or modification of therapy should be considered when marrow suppression is detected (see **DOSAGE AND ADMINISTRATION**).

Laboratory evaluation of renal and hepatic function should be performed prior to initiation of therapy and periodically thereafter (see **WARNINGS**).

**Carcinogenesis, Mutagenesis, Impairment of Fertility**—Long-term animal studies to evaluate the carcinogenic potential of Gemzar have not been conducted. Gemcitabine induced forward mutations *in vitro* in a mouse lymphoma (L5178Y) assay and was clastogenic in an *in vivo* mouse micronucleus assay. Gemcitabine was negative when tested using the Ames, *in vivo* sister chromatid exchange, and *in vitro* chromosomal aberration assays, and did not cause unscheduled DNA synthesis *in vitro*. Gemcitabine I.P. doses of 0.5 mg/kg/day (about 1/700 the human dose on a mg/m<sup>2</sup> basis) in male mice had an effect on fertility with moderate to severe hypospermatogenesis,



253 decreased fertility, and decreased implantations. In female mice fertility was not affected but maternal toxicities  
254 were observed at 1.5 mg/kg/day I.V. (about 1/200 the human dose on a mg/m<sup>2</sup> basis) and fetotoxicity or  
255 embryolethality was observed at 0.25 mg/kg/day I.V. (about 1/1300 the human dose on a mg/m<sup>2</sup> basis).

256 *Pregnancy* <sup>3</sup>/<sub>4</sub>Category D. See WARNINGS.

257 *Nursing Mothers* <sup>3</sup>/<sub>4</sub>It is not known whether Gemzar or its metabolites are excreted in human milk. Because many  
258 drugs are excreted in human milk and because of the potential for serious adverse reactions from Gemzar in nursing  
259 infants, the mother should be warned and a decision should be made whether to discontinue nursing or to  
260 discontinue the drug, taking into account the importance of the drug to the mother and the potential risk to the infant.

261 *Elderly Patients*—Gemzar clearance is affected by age (see **CLINICAL PHARMACOLOGY**). There is no  
262 evidence, however, that unusual dose adjustments, (i.e., other than those already recommended in the **DOSAGE**  
263 **AND ADMINISTRATION** section) are necessary in patients over 65, and, in general adverse reaction rates in the  
264 single-agent safety database of 979 patients were similar in patients above and below 65. Grade 3/4  
265 thrombocytopenia was more common in the elderly.

266 *Gender*—Gemzar clearance is affected by gender (see **CLINICAL PHARMACOLOGY**). In the single agent  
267 safety database (N=979 patients), however, there is no evidence that unusual dose adjustments (i.e., other than those  
268 already recommended in the **DOSAGE AND ADMINISTRATION** section) are necessary in women. In general, in  
269 single agent studies of gemcitabine adverse reaction rates were similar in men and women, but women, especially  
270 older women, were more likely not to proceed to a subsequent cycle and to experience grade 3/4 neutropenia and  
271 thrombocytopenia.

272 *Pediatric Patients* <sup>3</sup>/<sub>4</sub>Gemzar has not been studied in pediatric patients. Safety and effectiveness in pediatric  
273 patients have not been established.

274 *Patients with Renal or Hepatic Impairment*—Gemzar should be used with caution in patients with preexisting  
275 renal impairment or hepatic insufficiency. Gemzar has not been studied in patients with significant renal or hepatic  
276 impairment.

277 *Drug Interactions*—No specific drug interaction studies have been conducted. For information on the  
278 pharmacokinetics of Gemzar and cisplatin in combination, see *Drug Interactions* under **CLINICAL**  
279 **PHARMACOLOGY** section.

280 *Radiation Therapy*—Safe and effective regimens for the administration of Gemzar with therapeutic doses of  
281 radiation have not yet been determined.

282

283

## ADVERSE REACTIONS

284 Gemzar has been used in a wide variety of malignancies, both as a single agent and in combination with other  
285 cytotoxic drugs. The following discussion focuses on single agent use where the effects of Gemzar can be most  
286 readily determined and on the specific combination use that is the basis for its use in NSCLC.

287 **Single-Agent Use:** Myelosuppression is the principal dose-limiting toxicity with Gemzar therapy. Dosage  
288 adjustments for hematologic toxicity are frequently needed and are described in the **DOSAGE AND**  
289 **ADMINISTRATION** section.

290 The data in Table 4 are based on 979 patients receiving Gemzar as a single-agent administered weekly as a 30-  
291 minute infusion for treatment of a wide variety of malignancies. The Gemzar starting doses ranged from 800 to 1250  
292 mg/m<sup>2</sup>. Data are also shown for the subset of patients with pancreatic cancer treated in 5 clinical studies. The  
293 frequency of all grades and severe (WHO grade 3 or 4) adverse events were generally similar in the single-agent  
294 safety database of 979 patients and the subset of patients with pancreatic cancer. Adverse reactions reported in the  
295 single-agent safety database resulted in discontinuation of Gemzar therapy in about 10% of patients. In the  
296 comparative trial in pancreatic cancer, the discontinuation rate for adverse reactions was 14.3% for the gemcitabine  
297 arm and 4.8% for the 5-FU arm.

298 All WHO-graded laboratory events are listed in Table 4, regardless of causality. Non-laboratory adverse events  
299 listed in Table 4 or discussed below were those reported, regardless of causality, for at least 10% of all patients,  
300 except the categories of Extravasation, Allergic, and Cardiovascular and certain specific events under the Renal,  
301 Pulmonary, and Infection categories. Table 5 presents the data from the comparative trial of Gemzar and 5-FU in  
302 pancreatic cancer for the same adverse events as those in Table 4, regardless of incidence.

303 *Hematologic*—In studies in pancreatic cancer myelosuppression is the dose-limiting toxicity with Gemzar, but  
304 <1% of patients discontinued therapy for either anemia, leukopenia, or thrombocytopenia. Red blood cell  
305 transfusions were required by 19% of patients. The incidence of sepsis was less than 1%. Petechiae or mild blood  
306 loss (hemorrhage), from any cause, was reported in 16% of patients; less than 1% of patients required platelet

307 transfusions. Patients should be monitored for myelosuppression during Gemzar therapy and dosage modified or  
308 suspended according to the degree of hematologic toxicity (see **DOSAGE AND ADMINISTRATION**).

309 *Gastrointestinal*—Nausea and vomiting were commonly reported (69%) but were usually of mild to moderate  
310 severity. Severe nausea and vomiting (WHO grade 3/4) occurred in <15% of patients. Diarrhea was reported by 19%  
311 of patients, and stomatitis by 11% of patients.

312 *Hepatic*—In clinical trials, Gemzar was associated with transient elevations of one or both serum transaminases in  
313 approximately 70% of patients, but there was no evidence of increasing hepatic toxicity with either longer duration  
314 of exposure to Gemzar or with greater total cumulative dose. Serious hepatotoxicity, including liver failure and  
315 death, has been reported very rarely in patients receiving Gemzar alone or in combination with other potentially  
316 hepatotoxic drugs. (see *Hepatic* under Post-marketing experience.)

317 *Renal*—In clinical trials, mild proteinuria and hematuria were commonly reported. Clinical findings consistent  
318 with the hemolytic uremic syndrome (HUS) were reported in 6 of 2429 patients (0.25%) receiving Gemzar in  
319 clinical trials. Four patients developed HUS on Gemzar therapy, two immediately post-therapy. The diagnosis of  
320 HUS should be considered if the patient develops anemia with evidence of microangiopathic hemolysis, elevation of  
321 bilirubin or LDH, reticulocytosis, severe thrombocytopenia, and/or evidence of renal failure (elevation of serum  
322 creatinine or BUN). Gemzar therapy should be discontinued immediately. Renal failure may not be reversible even  
323 with discontinuation of therapy and dialysis may be required. (see *Renal* under Post-marketing experience)

324 *Fever*—The overall incidence of fever was 41%. This is in contrast to the incidence of infection (16%) and indicates  
325 that Gemzar may cause fever in the absence of clinical infection. Fever was frequently associated with other flu-like  
326 symptoms and was usually mild and clinically manageable.

327 *Rash*—Rash was reported in 30% of patients. The rash was typically a macular or finely granular maculopapular  
328 pruritic eruption of mild to moderate severity involving the trunk and extremities. Pruritus was reported for 13% of  
329 patients.

330 *Pulmonary*—In clinical trials, dyspnea, unrelated to underlying disease, has been reported in association with  
331 Gemzar therapy. Dyspnea was occasionally accompanied by bronchospasm. Pulmonary lung toxicity has been  
332 reported with the use of Gemzar (see *Pulmonary* under Post-marketing experience). The etiology of these effects is  
333 unknown. If such effects develop, Gemzar should be discontinued. Early use of supportive care measures may help  
334 ameliorate these conditions.

335 *Edema*—Edema (13%), peripheral edema (20%) and generalized edema (<1%) were reported. Less than 1% of  
336 patients discontinued due to edema.

337 *Flu-like Symptoms*—"Flu syndrome" was reported for 19% of patients. Individual symptoms of fever, asthenia,  
338 anorexia, headache, cough, chills, and myalgia were commonly reported. Fever and asthenia were also reported  
339 frequently as isolated symptoms. Insomnia, rhinitis, sweating, and malaise were reported infrequently. Less than 1%  
340 of patients discontinued due to flu-like symptoms.

341 *Infection*—Infections were reported for 16% of patients. Sepsis was rarely reported (<1%).

342 *Alopecia*—Hair loss, usually minimal, was reported by 15% of patients.

343 *Neurotoxicity*—There was a 10% incidence of mild paresthesias and a <1% rate of severe paresthesias.

344 *Extravasation*—Injection-site related events were reported for 4% of patients. There were no reports of injection  
345 site necrosis. Gemzar is not a vesicant.

346 *Allergic*—Bronchospasm was reported for less than 2% of patients. Anaphylactoid reaction has been reported  
347 rarely. Gemzar should not be administered to patients with a known hypersensitivity to this drug (see  
348 **CONTRAINDICATIONS**).

349 *Cardiovascular*—During clinical trials, 2% of patients discontinued therapy with Gemzar due to cardiovascular  
350 events such as myocardial infarction, cerebrovascular accident, arrhythmia, and hypertension. Many of these  
351 patients had a prior history of cardiovascular disease. (see *Cardiovascular* under Post-marketing experience)

352

353

354

355  
356  
357  
358

**Table 4**  
**Selected WHO-Graded Adverse Events in Patients Receiving**  
**Single Agent Gemzar**  
**WHO Grades (% incidence)**

	All Patients <sup>a</sup>			Pancreatic Cancer Patients <sup>b</sup>			<u>Discontinuations</u>
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4	(%) <sup>c</sup> All Patients
<b>Laboratory<sup>d</sup></b>							
Hematologic							
Anemia	68	7	1	73	8	2	<1
Leukopenia	62	9	<1	64	8	1	<1
Neutropenia	63	19	6	61	17	7	-
Thrombocytopenia	24	4	1	36	7	<1	<1
Hepatic							<1
ALT	68	8	2	72	10	1	
AST	67	6	2	78	12	5	
Alkaline Phosphatase	55	7	2	77	16	4	
Bilirubin	13	2	<1	26	6	2	
Renal							<1
Proteinuria	45	<1	0	32	<1	0	
Hematuria	35	<1	0	23	0	0	
BUN	16	0	0	15	0	0	
Creatinine	8	<1	0	6	0	0	
<b>Non-laboratory<sup>e</sup></b>							
Nausea and Vomiting	69	13	1	71	10	2	<1
Pain	48	9	<1	42	6	<1	<1
Fever	41	2	0	38	2	0	<1
Rash	30	<1	0	28	<1	0	<1
Dyspnea	23	3	<1	10	0	<1	<1
Constipation	23	1	<1	31	3	<1	0
Diarrhea	19	1	0	30	3	0	0
Hemorrhage	17	<1	<1	4	2	<1	<1
Infection	16	1	<1	10	2	<1	<1
Alopecia	15	<1	0	16	0	0	0
Stomatitis	11	<1	0	10	<1	0	<1
Somnolence	11	<1	<1	11	2	<1	<1
Paresthesias	10	<1	0	10	<1	0	0

359 Grade based on criteria from the World Health Organization (WHO)  
360 <sup>a</sup>N = 699-974; all patients with laboratory or non-laboratory data  
361 <sup>b</sup>N = 161-241; all pancreatic cancer patients with laboratory or non-laboratory data  
362 <sup>c</sup>N = 979  
363 <sup>d</sup>Regardless of causality  
364 <sup>e</sup>Table includes non-laboratory data with incidence for all patients ≥10%. For approximately 60% of the patients,  
365 non-laboratory events were graded only if assessed to be possibly drug-related.  
366

367  
368  
369  
370

**Table 5**  
**Selected WHO-Graded Adverse Events from Comparative Trial of Gemzar and 5-FU**  
**in Pancreatic Cancer**  
**WHO Grades (% incidence)**

	Gemzar <sup>a</sup>			5-FU <sup>b</sup>		
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4
<b>Laboratory<sup>c</sup></b>						
Hematologic						
Anemia	65	7	3	45	0	0
Leukopenia	71	10	0	15	2	0
Neutropenia	62	19	7	18	2	3
Thrombocytopenia	47	10	0	15	2	0
Hepatic						
ALT	72	8	2	38	0	0
AST	72	10	2	52	2	0
Alkaline Phosphatase	71	16	0	64	10	3
Bilirubin	16	2	2	25	6	3
Renal						
Proteinuria	10	0	0	2	0	0
Hematuria	13	0	0	0	0	0
BUN	8	0	0	10	0	0
Creatinine	2	0	0	0	0	0
<b>Non-laboratory<sup>d</sup></b>						
Nausea and Vomiting	64	10	3	58	5	0
Pain	10	2	0	7	0	0
Fever	30	0	0	16	0	0
Rash	24	0	0	13	0	0
Dyspnea	6	0	0	3	0	0
Constipation	10	3	0	11	2	0
Diarrhea	24	2	0	31	5	0
Hemorrhage	0	0	0	2	0	0
Infection	8	0	0	3	2	0
Alopecia	18	0	0	16	0	0
Stomatitis	14	0	0	15	0	0
Somnolence	5	2	0	7	2	0
Paresthesias	2	0	0	2	0	0

371 Grade based on criteria from the World Health Organization (WHO)  
372 <sup>a</sup>N = 58-63; all Gemzar patients with laboratory or non-laboratory data  
373 <sup>b</sup>N = 61-63; all 5-FU patients with laboratory or non-laboratory data.  
374 <sup>c</sup>Regardless of causality  
375 <sup>d</sup>Non-laboratory events were graded only if assessed to be possibly drug-related.

376 **Combination Use in Non-Small Cell Lung Cancer:** In the Gemzar plus cisplatin vs. cisplatin study, dose  
377 adjustments occurred with 35% of Gemzar injections and 17% of cisplatin injections on the combination arm, versus  
378 6% on the cisplatin only arm. Dose adjustments were required in greater than 90% of patients on the combination,  
379 versus 16% on cisplatin. Study discontinuations for possibly drug-related adverse events occurred in 15% of patients  
380 on the combination arm and 8% of patients on the cisplatin arm. With a median of 4 cycles of Gemzar plus cisplatin  
381 treatment, 94 of 262 patients (36%) experienced a total of 149 hospitalizations due to possibly treatment-related  
382 adverse events. With a median of 2 cycles of cisplatin treatment, 61 of 260 patients (23%) experienced 78  
383 hospitalizations due to possibly treatment-related adverse events.

384 In the Gemzar plus cisplatin vs. etoposide plus cisplatin study, dose adjustments occurred with 20% of Gemzar  
385 injections and 16% of cisplatin injections in the Gemzar plus cisplatin arm compared with 20% of etoposide  
386 injections and 15% of cisplatin injections in the etoposide plus cisplatin arm. With a median of 5 cycles of Gemzar  
387 plus cisplatin treatment, 15 of 69 patients (22%) experienced 15 hospitalizations due to possibly treatment-related  
388 adverse events. With a median of 4 cycles of etoposide plus cisplatin treatment, 18 of 66 patients (27%) experienced

389 22 hospitalizations due to possibly treatment related adverse events. In patients who completed more than one cycle,  
390 dose adjustments were reported in 81% of the Gemzar plus cisplatin patients, compared with 68% on the etoposide  
391 plus cisplatin arm. Study discontinuations for possibly drug-related adverse events occurred in 14% of patients on  
392 the gemcitabine plus cisplatin arm and in 8% of patients on the etoposide plus cisplatin arm. The incidence of  
393 myelosuppression was increased in frequency with Gemzar plus cisplatin treatment (~90%) compared to that with  
394 the Gemzar monotherapy (~60%). With combination therapy Gemzar dosage adjustments for hematologic toxicity  
395 were required more often while cisplatin dose adjustments were less frequently required.

396 Table 6 presents the safety data from the Gemzar plus cisplatin vs. cisplatin study in non-small cell lung cancer.  
397 The NCI Common Toxicity Criteria (CTC) were used. The two-drug combination was more myelosuppressive with  
398 four (1.5%) possibly treatment-related deaths, including three resulting from myelosuppression with infection and  
399 one case of renal failure associated with pancytopenia and infection. No deaths due to treatment were reported on  
400 the cisplatin arm. Nine cases of febrile neutropenia were reported on the combination therapy arm compared to two  
401 on the cisplatin arm. More patients required RBC and platelet transfusions on the Gemzar plus cisplatin arm.

402 Myelosuppression occurred more frequently on the combination arm, and in four possibly treatment-related deaths  
403 myelosuppression was observed. Sepsis was reported in 4% of patients on the Gemzar plus cisplatin arm compared  
404 to 1% on the cisplatin arm. Platelet transfusions were required in 21% of patients on the combination arm and <1%  
405 of patients on the cisplatin arm. Hemorrhagic events occurred in 14% of patients on the combination arm and 4% on  
406 the cisplatin arm. However, severe hemorrhagic events were rare. Red blood cell transfusions were required in 39%  
407 of the patients on the Gemzar plus cisplatin arm, versus 13% on the cisplatin arm. The data suggest cumulative  
408 anemia with continued Gemzar plus cisplatin use.

409 Nausea and vomiting despite the use of antiemetics occurred slightly more often with Gemzar plus cisplatin  
410 therapy (78%) than with cisplatin alone (71%). In studies with single-agent Gemzar, a lower incidence of nausea and  
411 vomiting (58%-69%) was reported. Renal function abnormalities, hypomagnesemia, neuromotor, neurocortical, and  
412 neurocerebellar toxicity occurred more often with Gemzar plus cisplatin than with cisplatin monotherapy.  
413 Neurohearing toxicity was similar on both arms.

414 Cardiac dysrhythmias of grade 3 or greater were reported in seven (3%) patients treated with Gemzar plus  
415 cisplatin compared to one (<1%) grade 3 dysrhythmia reported with cisplatin therapy. Hypomagnesemia and  
416 hypokalemia were associated with one grade 4 arrhythmia on the Gemzar plus cisplatin combination arm.

417 Table 7 presents data from the randomized study of Gemzar plus cisplatin versus etoposide plus cisplatin in 135  
418 patients with NSCLC for the same WHO-graded adverse events as those in Table 5. One death (1.5%) was reported  
419 on the Gemzar plus cisplatin arm due to febrile neutropenia associated with renal failure which was possibly  
420 treatment-related. No deaths related to treatment occurred on the etoposide plus cisplatin arm. The overall incidence  
421 of grade 4 neutropenia on the Gemzar plus cisplatin arm was less than on the etoposide plus cisplatin arm (28% vs.  
422 56%). Sepsis was experienced by 2% of patients on both treatment arms. Grade 3 anemia and grade 3/4  
423 thrombocytopenia were more common on the Gemzar plus cisplatin arm. RBC transfusions were given to 29% of  
424 the patients who received Gemzar plus cisplatin vs. 21% of patients who received etoposide plus cisplatin. Platelet  
425 transfusions were given to 3% of the patients who received Gemzar plus cisplatin vs. 8% of patients who received  
426 etoposide plus cisplatin. Grade 3/4 nausea and vomiting were also more common on the Gemzar plus cisplatin arm.  
427 On the Gemzar plus cisplatin arm, 7% of participants were hospitalized due to febrile neutropenia compared to 12%  
428 on the etoposide plus cisplatin arm. More than twice as many patients had dose reductions or omissions of a  
429 scheduled dose of Gemzar as compared to etoposide, which may explain the differences in the incidence of  
430 neutropenia and febrile neutropenia between treatment arms. Flu syndrome was reported by 3 % of patients on the  
431 Gemzar plus cisplatin arm with none reported on the comparator arm. Eight patients (12%) on the Gemzar plus  
432 cisplatin arm reported edema compared to one patient (2%) on the etoposide plus cisplatin arm.

**Table 6**  
**Selected CTC-Graded Adverse Events from Comparative Trial of Gemzar plus Cisplatin versus**  
**Single-Agent Cisplatin in NSCLC**  
**CTC Grades (% incidence)**

	<b>Gemzar plus Cisplatin<sup>a</sup></b>			<b>Cisplatin<sup>b</sup></b>		
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4
<b>Laboratory<sup>c</sup></b>						
Hematologic						
Anemia	89	22	3	67	6	1
RBC Transfusions <sup>d</sup>	39			13		
Leukopenia	82	35	11	25	2	1
Neutropenia	79	22	35	20	3	1
Thrombocytopenia	85	25	25	13	3	1
Platelet Transfusions <sup>d</sup>	21			<1		
Lymphocytes	75	25	18	51	12	5
<b>Hepatic</b>						
Transaminase	22	2	1	10	1	0
Alkaline Phosphatase	19	1	0	13	0	0
<b>Renal</b>						
Proteinuria	23	0	0	18	0	0
Hematuria	15	0	0	13	0	0
Creatinine	38	4	<1	31	2	<1
<b>Other Laboratory</b>						
Hyperglycemia	30	4	0	23	3	0
Hypomagnesemia	30	4	3	17	2	0
Hypocalcemia	18	2	0	7	0	<1
<b>Non- Laboratory<sup>e</sup></b>						
Nausea	93	25	2	87	20	<1
Vomiting	78	11	12	71	10	9
Alopecia	53	1	0	33	0	0
Neuro Motor	35	12	0	15	3	0
Constipation	28	3	0	21	0	0
Neuro Hearing	25	6	0	21	6	0
Diarrhea	24	2	2	13	0	0
Neuro Sensory	23	1	0	18	1	0
Infection	18	3	2	12	1	0
Fever	16	0	0	5	0	0
Neuro Cortical	16	3	1	9	1	0
Neuro Mood	16	1	0	10	1	0
Local	15	0	0	6	0	0
Neuro Headache	14	0	0	7	0	0
Stomatitis	14	1	0	5	0	0
Hemorrhage	14	1	0	4	0	0
Dyspnea	12	4	3	11	3	2
Hypotension	12	1	0	7	1	0
Rash	11	0	0	3	0	0

434 Grade based on Common Toxicity Criteria (CTC). Table includes data for adverse events with incidence  $\geq 10\%$  in either arm.

435 <sup>a</sup>N = 217-253; all Gemzar plus cisplatin patients with laboratory or non-laboratory data. Gemzar at 1000 mg/m<sup>2</sup> on Days 1, 8, and 15 and  
 436 cisplatin at 100 mg/m<sup>2</sup> on Day 1 every 28 days.

437 <sup>b</sup>N = 213-248; all cisplatin patients with laboratory or non-laboratory data. Cisplatin at 100 mg/m<sup>2</sup> on Day 1 every 28 days.

438 <sup>c</sup>Regardless of causality

439 <sup>d</sup>Percent of patients receiving transfusions. Percent transfusions are not CTC-graded events.

440 <sup>c</sup>Non-laboratory events were graded only if assessed to be possibly drug-related

**Table 7**

**Selected WHO-Graded Adverse Events from Comparative Trial of Gemzar plus Cisplatin versus Etoposide plus Cisplatin in NSCLC**

**WHO Grades (% incidence)**

	<b>Gemzar plus Cisplatin<sup>a</sup></b>			<b>Etoposide plus Cisplatin<sup>b</sup></b>		
	All Grades	Grade 3	Grade 4	All Grades	Grade 3	Grade 4
<b>Laboratory<sup>c</sup></b>						
Hematologic						
Anemia	88	22	0	77	13	2
RBC Transfusions <sup>d</sup>	29			21		
Leukopenia	86	26	3	87	36	7
Neutropenia	88	36	28	87	20	56
Thrombocytopenia	81	39	16	45	8	5
Platelet Transfusions <sup>d</sup>	3			8		
Hepatic						
ALT	6	0	0	12	0	0
AST	3	0	0	11	0	0
Alkaline Phosphatase	16	0	0	11	0	0
Bilirubin	0	0	0	0	0	0
Renal						
Proteinuria	12	0	0	5	0	0
Hematuria	22	0	0	10	0	0
BUN	6	0	0	4	0	0
Creatinine	2	0	0	2	0	0
<b>Non-Laboratory<sup>e,f</sup></b>						
Nausea and Vomiting	96	35	4	86	19	7
Fever	6	0	0	3	0	0
Rash	10	0	0	3	0	0
Dyspnea	1	0	1	3	0	0
Constipation	17	0	0	15	0	0
Diarrhea	14	1	1	13	0	2
Hemorrhage	9	0	3	3	0	3
Infection	28	3	1	21	8	0
Alopecia	77	13	0	92	51	0
Stomatitis	20	4	0	18	2	0
Somnolence	3	0	0	3	2	0
Paresthesias	38	0	0	16	2	0

441 Grade based on criteria from the World Health Organization (WHO)

442 <sup>a</sup>N = 67-69; all Gemzar plus cisplatin patients with laboratory or non-laboratory data. Gemzar at 1250 mg/m<sup>2</sup> on Days 1 and 8  
443 and cisplatin at 100 mg/m<sup>2</sup> on Day 1 every 21 days.

444 <sup>b</sup>N = 57-63; all cisplatin plus etoposide patients with laboratory or non-laboratory data. Cisplatin at 100 mg/m<sup>2</sup> on Day 1 and  
445 I.V. etoposide at 100 mg/m<sup>2</sup> on Days 1, 2, and 3 every 21 days.

446 <sup>c</sup>Regardless of causality.

447 <sup>d</sup>Percent of patients receiving transfusions. Percent transfusions are not CTC-graded events

448 <sup>e</sup>Non-laboratory events were graded only if assessed to be possibly drug-related.

449 <sup>f</sup>Pain data were not collected.

450

451

452  
453 **Post-marketing experience:** The following adverse events have been identified during post-approval use of  
454 Gemzar. These events have occurred after Gemzar single-agent use and Gemzar in combination with other cytotoxic  
455 agents. Decisions to include these events are based on the seriousness of the event, frequency of reporting, or  
456 potential causal connection to Gemzar.

457  
458 *Cardiovascular*—Congestive heart failure and myocardial infarction have been reported very rarely with the use of  
459 Gemzar. Arrhythmias, predominantly supraventricular in nature, have been reported very rarely.

460  
461 *Vascular Disorders*--Vascular toxicity reported with Gemzar includes clinical signs of vasculitis which has been  
462 reported very rarely. Gangrene has also been reported very rarely.

463  
464 *Skin*—Cellulitis and non-serious injection site reactions in the absence of extravasation have been rarely reported.

465  
466 *Hepatic*-- Serious hepatotoxicity, including liver failure and death has been reported very rarely in patients receiving  
467 Gemzar alone or in combination with other potentially hepatotoxic drugs.

468  
469 *Pulmonary*--Parenchymal toxicity, including interstitial pneumonitis, pulmonary fibrosis, pulmonary edema, and  
470 adult respiratory distress syndrome (ARDS) has been reported rarely following one or more doses of Gemzar  
471 administered to patients with various malignancies. Some patients experienced the onset of pulmonary symptoms up  
472 to two weeks after the last Gemzar dose. Respiratory failure and death occurred very rarely in some patients despite  
473 discontinuation of therapy.

474  
475 *Renal*—HUS and or renal failure have been reported following one or more doses of Gemzar. Renal failure leading  
476 to death or requiring dialysis, despite discontinuation of therapy, has been rarely reported. The majority of the cases  
477 of renal failure leading to death were due to HUS.

478

## 479 **OVERDOSAGE**

480 There is no known antidote for overdoses of Gemzar. Myelosuppression, paresthesias and severe rash were the  
481 principal toxicities seen when a single dose as high as 5700 mg/m<sup>2</sup> was administered by I.V. infusion over 30  
482 minutes every 2 weeks to several patients in a Phase 1 study. In the event of suspected overdose, the patient should  
483 be monitored with appropriate blood counts and should receive supportive therapy, as necessary.

484

## 485 **DOSAGE AND ADMINISTRATION**

486 *Gemzar is for intravenous use only.*

487 *Adults*

488 ***Single-Agent Use:***

489 **Pancreatic Cancer**—Gemzar should be administered by intravenous infusion at a dose of 1000 mg/m<sup>2</sup> over 30  
490 minutes once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a  
491 week of rest from treatment. Subsequent cycles should consist of infusions once weekly for 3 consecutive weeks out  
492 of every 4 weeks.

493 *Dose Modifications*—Dosage adjustment is based upon the degree of hematologic toxicity experienced by the  
494 patient (see **WARNINGS**). Clearance in women and the elderly is reduced and women were somewhat less able to  
495 progress to subsequent cycles (see **CLINICAL PHARMACOLOGY--Human Pharmacokinetics** and  
496 **PRECAUTIONS**).

497 Patients receiving Gemzar should be monitored prior to each dose with a complete blood count (CBC), including  
498 differential and platelet count. If marrow suppression is detected, therapy should be modified or suspended  
499 according to the guidelines in Table 8.



500  
501  
502

**Table 8**  
**Dosage Reduction Guidelines**

Absolute granulocyte count (x 10 <sup>6</sup> /L)		Platelet count (x 10 <sup>6</sup> /L)	% of full dose
≥1,000	and	≥100,000	100
500-999	or	50,000-99,000	75
<500	or	<50,000	Hold

503 Laboratory evaluation of renal and hepatic function, including transaminases and serum creatinine, should be  
504 performed prior to initiation of therapy and periodically thereafter. Gemzar should be administered with caution in  
505 patients with evidence of significant renal or hepatic impairment.

506 Patients treated with Gemzar who complete an entire cycle of therapy may have the dose for subsequent cycles  
507 increased by 25%, provided that the absolute granulocyte count (AGC) and platelet nadirs exceed 1500 x 10<sup>6</sup>/L and  
508 100,000 x 10<sup>6</sup>/L, respectively, and if non-hematologic toxicity has not been greater than WHO grade 1. If patients  
509 tolerate the subsequent course of Gemzar at the increased dose, the dose for the next cycle can be further increased by  
510 20%, provided again that the AGC and platelet nadirs exceed 1500 x 10<sup>6</sup>/L and 100,000 x 10<sup>6</sup>/L, respectively, and  
511 that non-hematologic toxicity has not been greater than WHO grade 1.

512 **Combination Use:**

513 **Non-Small Cell Lung Cancer**—Two schedules have been investigated and the optimum schedule has not been  
514 determined (see **CLINICAL STUDIES**). With the 4-week schedule, Gemzar should be administered intravenously  
515 at 1000 mg/m<sup>2</sup> over 30 minutes on days 1, 8, and 15 of each 28-day cycle. Cisplatin should be administered  
516 intravenously at 100 mg/m<sup>2</sup> on day 1 after the infusion of Gemzar. With the 3-week schedule, Gemzar should be  
517 administered intravenously at 1250 mg/m<sup>2</sup> over 30 minutes on days 1 and 8 of each 21-day cycle. Cisplatin at a dose  
518 of 100 mg/m<sup>2</sup> should be administered intravenously after the infusion of Gemzar on day 1. See prescribing  
519 information for cisplatin administration and hydration guidelines.

520 **Dose Modifications**—Dosage adjustments for hematologic toxicity may be required for Gemzar and for cisplatin.  
521 Gemzar dosage adjustment for hematological toxicity is based on the granulocyte and platelet counts taken on the  
522 day of therapy. Patients receiving Gemzar should be monitored prior to each dose with a complete blood count  
523 (CBC), including differential and platelet counts. If marrow suppression is detected, therapy should be modified or  
524 suspended according to the guidelines in Table 8. For cisplatin dosage adjustment, see manufacturer's prescribing  
525 information.

526 In general, for severe (grade 3 or 4) non-hematological toxicity, except alopecia and nausea/vomiting, therapy  
527 with Gemzar plus cisplatin should be held or decreased by 50% depending on the judgment of the treating physician.  
528 During combination therapy with cisplatin, serum creatinine, serum potassium, serum calcium, and serum  
529 magnesium should be carefully monitored (grade 3/4 serum creatinine toxicity for Gemzar plus cisplatin was 5%  
530 versus 2% for cisplatin alone).

531 Gemzar may be administered on an outpatient basis.

532 **Instructions for Use/Handling**—The recommended diluent for reconstitution of Gemzar is 0.9% Sodium Chloride  
533 Injection without preservatives. Due to solubility considerations, the maximum concentration for Gemzar upon  
534 reconstitution is 40 mg/mL. Reconstitution at concentrations greater than 40 mg/mL may result in incomplete  
535 dissolution, and should be avoided.

536 To reconstitute, add 5 mL of 0.9% Sodium Chloride Injection to the 200 mg vial or 25 mL of 0.9% Sodium  
537 Chloride Injection to the 1 g vial. Shake to dissolve. These dilutions each yield a gemcitabine concentration of 38  
538 mg/mL which includes accounting for the displacement volume of the lyophilized powder (0.26 mL for the 200 mg  
539 vial or 1.3 mL for the 1 g vial). The total volume upon reconstitution will be 5.26 mL or 26.3 mL, respectively.  
540 Complete withdrawal of the vial contents will provide 200 mg or 1 g of gemcitabine, respectively. The appropriate  
541 amount of drug may be administered as prepared or further diluted with 0.9% Sodium Chloride Injection to  
542 concentrations as low as 0.1 mg/mL.

543 Reconstituted Gemzar is a clear, colorless to light straw-colored solution. After reconstitution with 0.9% Sodium  
544 Chloride Injection, the pH of the resulting solution lies in the range of 2.7 to 3.3. The solution should be inspected  
545 visually for particulate matter and discoloration, prior to administration, whenever solution or container permit. If  
546 particulate matter or discoloration is found, do not administer.

547 When prepared as directed, Gemzar solutions are stable for 24 hours at controlled room temperature 20° to 25°C  
548 (68° to 77°F) [See USP]. Discard unused portion. Solutions of reconstituted Gemzar should not be refrigerated, as  
549 crystallization may occur.

550 The compatibility of Gemzar with other drugs has not been studied. No incompatibilities have been observed with  
551 infusion bottles or polyvinyl chloride bags and administration sets.

552 Unopened vials of Gemzar are stable until the expiration date indicated on the package when stored at controlled  
553 room temperature 20° to 25°C (68° to 77°F) [See USP].

554 Caution should be exercised in handling and preparing Gemzar solutions. The use of gloves is recommended. If  
555 Gemzar solution contacts the skin or mucosa, immediately wash the skin thoroughly with soap and water or rinse the  
556 mucosa with copious amounts of water. Although acute dermal irritation has not been observed in animal studies,  
557 two of three rabbits exhibited drug-related systemic toxicities (death, hypoactivity, nasal discharge, shallow  
558 breathing) due to dermal absorption.

559 Procedures for proper handling and disposal of anti-cancer drugs should be considered. Several guidelines on this  
560 subject have been published.<sup>1-7,8</sup> There is no general agreement that all of the procedures recommended in the  
561 guidelines are necessary or appropriate.

### 562 HOW SUPPLIED

563 Vials:

564 200 mg white, lyophilized powder in a 10 mL size sterile single use vial (No. 7501)

565 NDC 0002-7501-01

566 1 g white, lyophilized powder in a 50 mL size sterile single use vial (No. 7502)

567 NDC 0002-7502-01

568 Store at controlled room temperature (20° to 25°C) (68° to 77°F). The USP has defined controlled room  
569 temperature as "A temperature maintained thermostatically that encompasses the usual and customary working  
570 environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to be not more than  
571 25°C; and that allows for excursions between 15° and 30°C (59° and 86°F) that are experienced in pharmacies,  
572 hospitals, and warehouses."

### 573 REFERENCES

- 574
- 575 1. Recommendations for the safe handling of parenteral antineoplastic drugs. NIH publication No. 83-2621. US  
576 Government Printing Office, Washington, DC 20402.
  - 577 2. Council on Scientific Affairs: Guidelines for handling parenteral antineoplastics. *JAMA* 1985;253:1590.
  - 578 3. National Study Commission on Cytotoxic Exposure--Recommendations for handling cytotoxic agents, 1987.  
579 Available from Louis P Jeffrey, ScD, Director of Pharmacy Services, Rhode Island Hospital, 593 Eddy  
580 Street, Providence, Rhode Island 02902.
  - 581 4. Clinical Oncological Society of Australia: Guidelines and recommendations for safe handling of  
582 antineoplastic agents. *Med J Aust* 1983;1:426.
  - 583 5. Jones RB, et al. Safe handling of chemotherapeutic agents: A report from the Mount Sinai Medical Center.  
584 *CA* 1983;33(Sept/Oct): 258.
  - 585 6. American Society of Hospital Pharmacists: Technical assistance bulletin on handling cytotoxic drugs in  
586 hospitals. *Am J Hosp Pharm* 1990;47:1033.
  - 587 ~~7. Yodaiken RE, Bennet D Controlling Occupational Exposure to Hazardous Drugs, OSHA workWork-practice~~  
588 ~~Practice guidelines-Guidelines. for personnel dealing with cytotoxic (antineoplastic) drugs. *Am J Hosp Pharm*~~  
589 ~~1988;43:1193-1204. *Am J Health-Sys Pharm.* 1996;53-1669-1685.~~  
590 ~~8. ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice.~~  
591 ~~Pittsburgh, PA: Oncology Nursing Society; 1999:32-41.~~  
592

593  
594  
595  
596  
597 **Eli Lilly and Company**  
598 **Indianapolis, IN 46285, USA**  
599